Detalles de la búsqueda
1.
Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
BMC Cancer
; 18(1): 982, 2018 Oct 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30326862
2.
High levels of serum CA15-3 and residual invasive tumor size are associated with poor prognosis for breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy.
J Surg Oncol
; 118(1): 228-237, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29936704
3.
Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
World J Surg Oncol
; 16(1): 26, 2018 Feb 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29433529
4.
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel.
Clin Breast Cancer
; 18(5): 400-409, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29605174
5.
Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.
PLoS One
; 12(9): e0184508, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28886153
Resultados
1 -
5
de 5
1
Próxima >
>>